Treatment-free interval as a determinant of second-line chemotherapy outcomes in extensive-stage small cell lung cancer: a Dutch population-based study

Lung, Respiratory and Thoracic Cancer

Real-World Treatment Patterns and Clinical Outcomes in Patients With Extensive-Stage Small Cell Lung Cancer Treated With First-Line Platinum-Based Chemotherapy and ≥ 2 Subsequent Lines of Therapy in the United States

Adv Ther

Sankar K, Unni S, Eberl M, Le H, Herrmann T, Gorsh B, Tang M, Coerts F, Ahmed S

doi: 10.1007/s12325-025-03408-z

Lung, Respiratory and Thoracic CancerCOVID-19

Treatment and outcomes of limited stage small cell lung cancer in the Canadian small cell lung cancer database (CASCADE)

Lung Cancer

Phillips WJ, Zhan LJ, Chowdhury D, Gill J, Sun A, Rittberg R, Cohen V, Gibson AJW, Yan M, Liwski D, Surapaneni S, D'Amours MF, Yu FPS, Kim Y, Qadeer RA, Dawe DE, Agulnik J, Navani V, Fung AS, Snow S, Kuruvilla S, Ho C, Lok BH, Liu G, Wheatley-Price P, Moore S

doi: 10.1016/j.lungcan.2025.108840

Lung, Respiratory and Thoracic Cancer

Clinical characteristics and survival of small cell lung cancer with limited or extensive synchronous metastatic spread - A German population-based cancer-registry based cohort study

Lung Cancer

Schliemann A, Waldmann A, Katalinic A, Kim-Wanner SZ, Pritzkuleit R, Twardella D, Bertram S

doi: 10.1016/j.lungcan.2026.109448

Lung, Respiratory and Thoracic Cancer

Mutation testing, treatment patterns, and outcomes in patients with unresectable stage III EGFR-mutated non-small cell lung cancer treated with chemoradiotherapy: Final analysis of a global real-world study

Lung Cancer

Ahn MJ, Lin SH, Yang CT, Lee JB, Neal JW, Okishio K, Nishino K, Smith D, Rauter M, Jimenez M, Nasirova F, Kim Y

doi: 10.1016/j.lungcan.2025.108748

Lung, Respiratory and Thoracic Cancer

Real-world clinical characteristics and outcomes in patients with HER2-mutant non-small cell lung cancer (NSCLC) who received second-line treatment: A nationwide database analysis in Japan

Lung Cancer

Uehara Y, Ikegami M, Kohsaka S, Kimura H, Mizushima M, Okuma Y

doi: 10.1016/j.lungcan.2026.109491

SPECIAL REPORT

Lung, Respiratory and Thoracic Cancer

IMDYLLTRA^® in Relapsed Small Cell Lung Cancer: Translating a New T-cell Engager Approach into Clinical Practice

Lung, Respiratory and Thoracic Cancer

Second-line chemotherapy efficacy is not affected by prior exposure to immunotherapy in extensive-disease small-cell lung cancer: results from the ESME French national real-world cohort

ESMO Open

Gobbini E, Diallo MH, Clément-Duchene C, Chouaid C, Hiret S, Audigier-Valette C, Bizieux A, Debieuvre D, Quantin X, Le Guen Y, Lemoine A, Falchero L, Remon-Masip J, Bosquet L, Pérol M, Girard N

doi: 10.1016/j.esmoop.2026.108324

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

Real-world outcomes versus clinical trial results of first-line immunotherapy with or without chemotherapy in patients with metastatic non-small-cell lung cancer: the CORRELATE study

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

ESMO Open

Peters S, Salomonsen RJ, Diaz Perez I, Shcherbakova T, Wang A, Cai L, Sadow S, Liu SV

doi: 10.1016/j.esmoop.2025.106031

Lung, Respiratory and Thoracic Cancer

Cost-effectiveness of adjuvant alectinib in the treatment of patients with resected stage IB-IIIA ALK-positive non-small lung cancer in France, based on the ALINA study

Lung Cancer

Supiot R, Gherardi A, du Manoir de Juaye L, Doghri O, Sivignon M, Duruisseaux M, Chouaid C

doi: 10.1016/j.lungcan.2025.108885

Related content

Real-World Treatment Patterns and Clinical Outcomes in Patients With Extensive-Stage Small Cell Lung Cancer Treated With First-Line Platinum-Based Chemotherapy and ≥ 2 Subsequent Lines of Therapy in the United States

Treatment and outcomes of limited stage small cell lung cancer in the Canadian small cell lung cancer database (CASCADE)

Clinical characteristics and survival of small cell lung cancer with limited or extensive synchronous metastatic spread - A German population-based cancer-registry based cohort study

Mutation testing, treatment patterns, and outcomes in patients with unresectable stage III EGFR-mutated non-small cell lung cancer treated with chemoradiotherapy: Final analysis of a global real-world study

Real-world clinical characteristics and outcomes in patients with HER2-mutant non-small cell lung cancer (NSCLC) who received second-line treatment: A nationwide database analysis in Japan

IMDYLLTRA® in Relapsed Small Cell Lung Cancer: Translating a New T-cell Engager Approach into Clinical Practice

Second-line chemotherapy efficacy is not affected by prior exposure to immunotherapy in extensive-disease small-cell lung cancer: results from the ESME French national real-world cohort

Real-world outcomes versus clinical trial results of first-line immunotherapy with or without chemotherapy in patients with metastatic non-small-cell lung cancer: the CORRELATE study

Cost-effectiveness of adjuvant alectinib in the treatment of patients with resected stage IB-IIIA ALK-positive non-small lung cancer in France, based on the ALINA study

IMDYLLTRA^® in Relapsed Small Cell Lung Cancer: Translating a New T-cell Engager Approach into Clinical Practice